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COVID-19 as an Example of Why 
Genomic Sequence Data Should 
Remain Patent Ineligible
Jorge L. Contreras, JD, University of Utah S.J. Quinney College of Law and University of Utah School of Medicine
SUMMARY. The researchers who determined the genomic sequence of the SARS-CoV-2 virus did not seek 
to patent it, but instead released it in the publicly-accessible GenBank data repository. Their release of 
this critical data enabled the scientific community to mobilize rapidly and conduct research on a range of 
diagnostic, vaccine, and therapeutic applications based on the viral RNA sequence. Had the researchers 
sought patent protection for their discovery, as earlier research teams had during the SARS, H1N1 and H5N1 
outbreaks, global research relating to COVID-19 would have been less efficient and more costly. One of the 
reasons that patents are no longer sought on genomic sequences is the U.S. Supreme Court’s decision in 
Association for Molecular Pathology v. Myriad Genetics, Inc., which established that a sequence of naturally-
occurring nucleotides is an unpatentable “product of nature” (Association for Molecular Pathology v. Myriad 
Genetics, 2013). Yet, in the midst of the COVID-19 crisis, patent advocates are calling on Congress to overturn 
the Myriad decision and once again allow patenting of genomic sequences. This Chapter argues that the 
COVID-19 pandemic illustrates why the “product of nature” exclusion under patent law, which prevents the 
patenting of genomic sequence data, should be preserved and strengthened under U.S. law.
Introduction
From the beginning of the COVID-19 pandemic, governments, 
health care advocates, and scholars around the world expressed 
concern that patents could slow the manufacture and distribution 
of medical supplies, equipment, vaccines, and therapies to 
populations most in need of them. Chapter 21 of Assessing Legal 
Responses to COVID-19: Volume I, discusses potential policy 
responses to these concerns, including the exercise of government 
use rights, the imposition of access conditions on research funding 
and public procurement, and the encouragement of patent pools. 
Yet amidst the debate over patents relating to the pandemic 
response, one significant discovery has remained free from patent 
claims: the genomic sequence of the SARS-CoV-2 virus itself. 
Genomic Patents in the United States
The genomic RNA sequence of SARS-CoV-2 (the viral infectious 
agent responsible for COVID-19) was first elucidated in January, 
2020, by a team of 19 researchers at four Chinese universities and 
public health agencies. They published their findings in the journal 
Nature and released the sequence to the publicly-accessible 
GenBank database maintained by the U.S. National Center for 
Biotechnology Information (Wu et al., 2020). The SARS-CoV-2 
sequence and its many emerging variants have  proved invaluable 
to research concerning the virus. Yet these sequences are not 
known to be subject to any pending or issued patent claims and are 
thus available without restriction to public and private researchers 
around the world.
Myriad and Products of Nature
One reason that the SARS-CoV-2 sequence has not been patented, 
at least in the United States, is due to the U.S. Supreme Court’s 
decision in Association for Molecular Pathology v. Myriad Genetics, 
Inc., which established that a sequence of naturally-occurring 
nucleotides is an unpatentable “product of nature” (technically, the 
case related to DNA rather than RNA sequences, but the Court’s 
reasoning applies to both molecules with equal force) (Association 
for Molecular Pathology v. Myriad Genetics, 2013). While the Court 
held that patents might be available on “new applications of 
knowledge,” genes themselves, and their nucleotide sequences, 
are ineligible subject matter for patent protection. 
Legislative Efforts to Overrule Myriad
The Myriad decision, together with the Supreme Court’s earlier 
decision in Mayo Collaborative Services v. Prometheus Laboratories, 
Inc., have been portrayed as effectively eliminating the possibility 
of patents for genetic diagnostics — a potentially devastating result 
for the diagnostics industry (Eisenberg, 2015; Mayo Collaborative 
Services. v. Prometheus Laboratories, Inc., 2012). As a result, 
advocates of stronger patent protection have steadfastly sought to 
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overturn the Myriad and Mayo decisions through legislative means. 
In 2019, Senators Chris Coons and Thom Tillis introduced legislation 
that would have abrogated any “implicit or judicially created 
exceptions to [patent] subject matter eligibility including ‘abstract 
ideas,’ ‘laws of nature,’ or ‘natural phenomena.’” The effect of these 
provisions would have been to permit, once again, the patenting 
of any previously undiscovered natural substance or genomic 
sequence. 
In addition to genetic data, the Coons-Tillis proposal sought 
to address the patentability of other controversial inventions 
including software, medical diagnostic methods, and methods of 
conducting business. As a result, opposition arose from numerous 
quarters. Notably, 160 civil rights, medical, scientific, patient 
advocacy, and women’s health organizations openly opposed the 
Coons-Tillis bill, arguing that if the bill were enacted, “Patients will 
again be at risk of lacking access to information about their genes, 
about their very selves. We likely will again see high prices for tests 
with no competition in the market, and harms to innovation and 
useful research with no guarantee that the law would eventually 
provide the same protections that it now offers” (American Civil 
Liberties Union et al., 2019). The Senate Judiciary Committee held 
three sets of hearings on the bill in 2019, after which the draft 
legislation stalled.
Despite the failure of this legislative attempt to reverse the 
Myriad decision, the emergence of the COVID-19 pandemic in 
early 2020 led to renewed calls for increased patent protection of 
biomedical discoveries. Thus, at the same time that advocates and 
governments around the world were calling for the relaxation of 
patent restrictions to address the supply of critical supplies and 
equipment in response to the pandemic, patent advocates blamed 
the lack of reliable diagnostic tests, vaccines, and treatments for 
COVID-19 on too little patent protection. Senator Tillis commented 
in one interview, “The way the current jurisprudence sits, there’s 
almost no incentive to develop new, innovative diagnostic testing 
methods or other life-saving treatments. As the COVID-19 pandemic 
is unfortunately showing us, having these tests in the pipeline are 
crucial for public and economic health, well-being, and safety” 
(Quinn, 2020). 
During the course of the pandemic, the U.S. Patent and Trademark 
Office (PTO) introduced new programs to accelerate the 
examination and issuance of patents covering COVID-19 related 
inventions, and Senator Ben Sasse introduced legislation that 
would, among other things, add 10 years to the term of COVID-related 
patents (Facilitating Innovation to Fight Coronavirus Act, 2020). 
In early 2021, new legislative proposals to strengthen patents, 
including by Senators Tillis and Coons, began to percolate as 
the Biden administration prepared to take office. Yet despite 
unsubstantiated claims that increased patent protection would 
have facilitated the speedier development and deployment of 
COVID-related diagnostics, vaccines, and therapies, there is 
ample evidence to suggest that, at least in the case of genomic 
sequences, a return to the days of patenting would have been 
counterproductive.
The Value of Open Genomic Data
The Genomic Commons
Since the Human Genome Project (HGP) (1988-2003), the field 
of genomic research has been characterized by norms of 
international collaboration and data sharing. Explicit patent 
deterrence strategies were embodied in the data sharing policies 
adopted by the governmental and philanthropic funding agencies 
that supported this research, resulting in a vast aggregation 
of genomic data that is available to researchers around the 
world — the “Genomic Commons” (Contreras & Knoppers, 2018). 
Contributions to this public store of knowledge were made not only 
by governmental and academic laboratories, but by pharmaceutical 
and biotechnology companies (Contreras & Knoppers, 2018). 
Research has shown that the public availability of genomic data 
from the HGP has significantly enhanced scientific research as 
compared to data that is maintained as proprietary (Williams, 2013).
The Gene Patenting Race
Despite the growth of the public genomic commons, a 
countervailing trend emerged in the late 1980s and early 1990s 
toward private patenting of genomic discoveries. The patents 
issued to Myriad Genetics covering the BRCA1 and BRCA2 
genes, which are linked to familial breast and ovarian cancer, 
were examples of this growing phenomenon. By 2005, two MIT 
researchers estimated that a full 20% of known human genes were 
covered by patents (Jensen & Murray, 2005). While the PTO rejected 
the patentability of short DNA segments having unknown utility, 
larger segments of DNA constituting full genes were deemed to be 
patentable as new “compositions of matter” (Sherkow & Greely, 2015). 
The Virus Patent Races
Patents during this period were not limited to human genomic 
sequences. Nucleotide sequences of plants, model organisms, 
bacteria and viruses were also being patented. As documented by 
Queensland University of Technology professor Matthew Rimmer, 
a contentious international “race” to identify and patent the RNA 
sequence of the SARS virus occurred shortly after the outbreak 
of the epidemic in 2002 (Rimmer, 2004). Research institutions 
in North America, Europe, and Asia each rushed to file patent 
applications “broad enough to allow their holders to claim rights 
in most diagnostic tests, drugs, or vaccines that have been or 
would be developed to cope with the outbreak” (Rimmer, 2004). 
Among the negative outcomes of this patenting race was the 
emergence of a patent “thicket” in the area of SARS research and 
the unsuccessful attempt to pool these patents for broader use 
(Beldiman, 2012). Similarly dysfunctional scenarios played out a few 
years later with the H1N1 and H1N5 influenza outbreaks (Greene, 
2010; Beldiman, 2012). 
Unlike these prior outbreaks, there does not appear to have been 
a rush to patent the SARS-CoV-2 genomic sequence. This lack of 
patenting is due both to the rapid public release of the sequence 
by the researchers who first identified it (i.e., acting as prior art 
to defeat patents that might later be filed (Contreras & Knoppers, 
2018)) and the presumption against genomic sequence patents 
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established in the United States by the Myriad decision. This 
“patent free zone” enabled rapid international collaboration on 
basic research concerning COVID-19.
Why Patents on Genomic Sequences Should Not, and 
Need Not, Be Allowed
Despite vociferous calls for more patenting of technologies 
pertinent to COVID-19, Congress should resist legislative attempts 
to overrule the Myriad decision and its ban on patenting genomic 
sequence information.
Genomic Sequence Data is a Basic Research Tool that Should be 
Broadly Available
A vast array of basic scientific research is enabled by knowledge 
of an organism’s genomic sequence. This research can lead to a 
better understanding of biochemical mechanisms and to medical 
innovations such as vaccines and therapeutics. As such, genomic 
sequence data are a form of basic “research tool” — a resource that 
can be used by multiple researchers to address different research 
questions. There is a broad policy consensus that research tools 
should be made as broadly available as possible to the research 
community (National Institutes of Health, 1999). Allowing one or 
a handful of entities to own this basic scientific information can 
hinder research when speed and international collaboration are 
needed most. Studies have shown that researchers were reluctant 
to study the patented BRCA genes, thereby reducing overall 
knowledge and scientific advancement, something that cannot be 
afforded in the face of an emergent global pandemic.
Composition of Matter Patents Preempt all Uses of a Sequence
Because patents can claim genomic sequences as new 
“compositions of matter” (like polymers or metallic alloys), they 
preempt all possible uses of the patented sequences, whether 
or not envisioned by the patent holder (Contreras, 2020). The 
Supreme Court correctly recognized in Myriad that genomic 
sequences of biological organisms are not new forms of matter, 
even if they are isolated and purified in the laboratory. Reversing 
this holding would again allow individual patent holders to control 
all uses of a particular genomic sequence, thereby creating 
significant bottlenecks to effective research and development and 
granting patent holders a windfall with respect to applications of a 
discovery that they did not actually make.
Composition of Matter Patents Discourage Improvements
Because broad composition of matter patents cover all uses of a 
patented gene or variant, any improvement to a diagnostic test that 
the patent holder makes will likely be covered by its own patents.  
And because competitors are not permitted to offer competing 
diagnostic tests, a patent holder has little incentive to improve 
its own diagnostic tests once a patent is issued. That is, its broad 
patent is likely to cover both the original and improved tests, and 
no competing tests are allowed, giving the patent holder little 
motivation to improve the tests over which it already has monopoly 
control. 
Patents Are Not Needed to Incentivize the Discovery of Genomic 
Sequences
As noted above, today a vast body of human and non-human 
genomic sequence data is available to researchers in public 
repositories (Contreras & Knoppers, 2018). The discovery of this 
data was largely supported by government and philanthropic 
funding sources. With advances in sequencing technology and 
a global recognition that genomic sequence data represent a 
scientific resource for all, the sequencing of new biological entities 
such as emergent viral strains can be, and is, accomplished quickly 
and efficiently through existing government-funded programs. 
The sequencing of the SARS-CoV-2 virus by a coalition of Chinese 
university and public health agencies (Wu et al., 2020), with no 
attempt to patent their results, demonstrates this reality. Since 
then, substantial scientific advances have been made as new 
variants and mutations of the SARS-CoV-2 virus have emerged 
during the course of the pandemic. As such, arguments that 
patenting is required to induce private actors to invest in this work 
are simply not applicable to the derivation of genomic sequence 
data today.
There is Ample Opportunity for Patent Protection of Medical 
Innovations Without Claiming Genomic Sequences
A large number of patents exist and continue to be obtained on 
innovations relating to COVID-19, including protective equipment, 
medical devices, tracing and modeling algorithms, diagnostic 
kits, vaccines, and therapeutics (Tietze et al., 2020). As such, 
ample private incentives — both in terms of patent royalties and 
procurement payments — exist to promote the development 
of needed technologies like these. Basic genomic structures, 
however, are research tools, not products or product components. 
As such, allowing them to be patented does no more than enable 
the holders of those patents to impose a tax on the industry 
that is developing products that rely on this basic scientific 
information. Had the basic genomic sequence of the SARS-CoV-2 
been patented, as had the sequences of the SARS, H1N1 and H1N5 
viruses, the development of desperately needed vaccines and 
therapies would have been delayed or, at best, made more costly to 
consumers and health care providers.
Patents on Genomic Sequences Increase Costs and Reduce 
Access to Medical Innovations
Myriad Genetics priced its genetic tests at a level beyond the 
means of many individuals, leading to widespread criticism of the 
company and the patents that gave it a monopoly over testing the 
BRCA1/2 genes. Issues surrounding access to genetic testing thus 
lay at the heart of the Myriad litigation. The issue of access was 
central to the American Civil Liberties Union, which brought the 
case, and its recruitment of numerous patient advocacy groups, 
health care providers, and medical societies as plaintiffs and amici 
curiae (Contreras, 2020). The Supreme Court’s decision invalidating 
most of Myriad’s gene patents was widely heralded as a victory 
for health care access. A return to the days of genomic sequence 
patents would reverse this victory and again enable private firms to 
wield legal exclusivity to increase patient costs, burden the health 
care system, and exclude those most in need from critical medical 
innovations.
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Recommendation for Action
 Federal government:
• Congress should reject legislative proposals that seek to 
overrule the ban on patenting naturally-occurring genomic 
sequences that was established by the Supreme Court in 
Association for Molecular Pathology v. Myriad Genetics, Inc. 
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